Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval-Reference-Cited by-同舟云学术

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

Published:2015-09-15 Issue:11 Volume:107 Page:djv253
ISSN:0027-8874
Container-title:Journal of the National Cancer Institute
language:en
Short-container-title:JNCI.J

Author:

Fontes Jardim Denis L.,Schwaederle Maria,Wei Caimiao,Lee J. Jack,Hong David S.,Eggermont Alexander M.,Schilsky Richard L.,Mendelsohn John,Lazar Vladimir,Kurzrock Razelle

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/107/11/djv253/17986382/djv253.pdf

Reference42 articles.

1. First FDA Authorization for Next-Generation Sequencer

2. Targeted cancer therapy

3. National Cancer Institute: Targeted cancer therapies. Fact Sheet. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted Accessed November 25, 2013.

4. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

5. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer;Targeted Oncology;2024-08-10

2. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results;Acta Oncologica;2024-05-23

3. Next-Generation Sequencing Trends among Adult Patients with Select Advanced Tumor Types;The Journal of Molecular Diagnostics;2024-04

4. Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design;Cancer Treatment Reviews;2024-04

5. Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel;Cancer Medicine;2024-03-30